Feeds:
Posts
Comments

Posts Tagged ‘Evolving approaches including combination oncotherapy’


Immune System Stimulants: Articles of Note @pharmaceuticalintelligence.com

Curators: Larry H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN

 

  • New Approaches to Immunotherapy

 

New Class of Immune System Stimulants: Cyclic Di-Nucleotides (CDN): Shrink Tumors and bolster Vaccines, re-arm the Immune System’s Natural Killer Cells, which attack Cancer Cells and Virus-infected Cells

Three Methods for Design of a Novel Immune Therapy for Cancer: Conceptual Foundation for Development of a Novel Mechanism of Action for a Combination Therapy of Biologics — Password protected

Basic Research in Immune Oncology and Molecular Genomics: Methods to Stimulate Immunity by Alteration of Tumor Antigens – Reporting on R&D @MGH

New insights in cancer, cancer immunogenesis and circulating cancer cells

Perspectives on Anti-metastatic Effects in Cancer Research 2015

 

 

Issues Need to be Resolved With Immuno-Modulatory Therapies: NK cells, mAbs, and adoptive T cells

 

  •  Current Methods of Immuno-Therapy

 

 

Checkpoint inhibitors for gastrointestinal cancers

Immunomodulatory Therapeutic Antibodies for Cancer, August 13-15, 2013 – Boston, MA – Final Agenda

Tang Prize for 2014: Immunity and Cancer

LIVE 10:25 am – 12:00 pm 4/26/2016 Fireside Chat: Robert Bradway, CEO, Amgen & Immunotherapy I: Checkpoint Activation and Cancer Vaccines @2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Westin Hotel, Boston

Natural Killer Cell Response: Treatment of Cancer

CANCER IMMUNOTHERAPY

Cancer Immunotherapy Conference & Biomarkers for Cancer Immunotherapy Symposium, March 6-11, 2016 | Moscone North Convention Center | San Francisco, CA

Viruses, Vaccines and Immunotherapy

Advances in Cancer Immunotherapy

Perspectives on Anti-metastatic Effects in Cancer Research 2015

 

  • Evolving Approaches including Combination Oncotherapy

 

LIVE – 8:00 am – 12:00 pm 4/25/2016 – First Look: The Next Wave of Cancer Breakthroughs @2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Westin Hotel, Boston 2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Partners HealthCare, Boston, at the Westin Hotel, Boston

Brain Cancer Vaccine in Development and other considerations

Rapid regression of HER2 breast cancer

Breakthrough work in cancer

Novel biomarkers for targeting cancer immunotherapy

Humanized Mice May Revolutionize Cancer Drug Discovery

Immunomodulatory Therapeutic Antibodies for Cancer, August 13-15, 2013 – Boston, MA – Final Agenda

Melanoma: Molecule in Immune System Could Help Treat Dangerous Skin Cancer

NIH Study Demonstrates that a New Cancer Immunotherapy Method could be Effective against a wide range of Cancers

Aptamers and Scaffolds

 

  • Microbiological Factors in Cancer Growth

 

Microbe meets cancer

Gut microbiome and anti-tumor response

Malaria Protein Anti-cancer Activity

Retroviruses and Immunity

Oncolytic Viruses in Cancer Therapy @ CHI’s PreClinical Congress, June 14, 2016 Westin Boston Waterfront, Boston

Oncolytic Virus Immuno-Therapy: New Approach for a New Class of Immunotherapy Drugs

 

  • Signaling Pathways in Oncotherapy

 

Protein heals wounds, boosts immunity and protects from cancer – Lactoferrin

Programmed Cell Death and Cancer Therapy

BET Proteins Connect Diabetes and Cancer

Signaling of Immune Response in Colon Cancer

Myc and Cancer Resistance

Renal (Kidney) Cancer: Connections in Metabolism at Krebs cycle and Histone Modulation

Pancreatic Cancer and Crossing Roads of Metabolism

Autophagy-Modulating Proteins and Small Molecules Candidate Targets for Cancer Therapy: Commentary of Bioinformatics Approaches

A Curated Census of Autophagy-Modulating Proteins and Small Molecules Candidate Targets for Cancer Therapy

Biology, Physiology and Pathophysiology of Heat Shock Proteins

Heat Shock Proteins (HSP) and Molecular Chaperones

The Delicate Connection: IDO (Indolamine 2, 3 dehydrogenase) and Cancer Immunology

What is the key method to harness Inflammation to close the doors for many complex diseases?

IDO for Commitment of a Life Time: The Origins and Mechanisms of IDO, indolamine 2, 3-dioxygenase

Confined Indolamine 2, 3 dioxygenase (IDO) Controls the Hemeostasis of Immune Responses for Good and Bad

Insight on Cell Senescence

Neutrophil Serine Proteases in Disease and Therapeutic Considerations

T cell-mediated immune responses & signaling pathways activated by TLRs

 

  • Immunogenetics in Oncotherapy

 

CRISPR/Cas9: Contributions on Endoribonuclease Structure and Function, Role in Immunity and Applications in Genome Engineering

CRISPR-Cas9 and Regenerative Medicine

CRISPR/Cas9 Finds Its Way As an Important Tool For Drug Discovery & Development

GEN Tech Focus: Rethinking Gene Expression Analysis

Gene Expression and Adaptive Immune Resistance Mechanisms in Lymphoma

Serpins: A Review in Human Genomics

Upcoming Meetings on Cancer Immunogenetics

ipilimumab, a Drug that blocks CTLA-4 Freeing T cells to Attack Tumors @DM Anderson Cancer Center

NIH Considers Guidelines for CAR-T therapy: Report from Recombinant DNA Advisory Committee

Cancer Labs at School of Medicine @ Technion: Janet and David Polak Cancer and Vascular Biology Research Center

Host – Tumor Interactions during Cancer Therapy – Dr. Yuval Shaked’s Lab @Technion

Demythologizing sharks, cancer, and shark fins

Naked Mole Rats Cancer-Free

From the Walter and Eliza Hall Institute of Medical Research: Genes Needed for Local Tissue Immune Response

 

  • Immunotherapy Market

 

Next-generation Universal Cell Immunotherapy startup Adicet Bio, Menlo Park, CA is launched with $51M Funding by OrbiMed

Juno Acquires AbVitro for $125M: high-throughput and single-cell sequencing capabilities for Immune-Oncology Drug Discovery

Monoclonal Antibody Therapy and Market

Monoclonal Antibody Therapy: What is in the name or clear description?

Tumor Associated Macrophages: The Double-Edged Sword Resolved?

Targeting Glucose Deprived Network Along with Targeted Cancer Therapy Can be a Possible Method of Treatment

Immunoreactivity of Nanoparticles 

Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis

Acute Lung Injury

Peroxisome proliferator-activated receptor (PPAR-gamma) Receptors Activation: PPARγ transrepression for Angiogenesis in Cardiovascular Disease and PPARγ transactivation for Treatment of Diabetes

Inflammatory Disorders: Articles published @ pharmaceuticalintelligence.com

Cytokines in IBD

Read Full Post »